Urogen Pharma (URGN) Received its Third Buy in a Row
After H.C. Wainwright and Stifel Nicolaus gave Urogen Pharma (NASDAQ: URGN) a Buy rating last month, the company received another Buy, this time from Oppenheimer. Analyst Leland Gershell maintained a Buy rating on Urogen Pharma yesterday and set a price target of $47.00. The company’s shares closed last Thursday at $22.14.
According to TipRanks.com, Gershell is a 4-star analyst with an average return of 7.8% and a 46.5% success rate. Gershell covers the Healthcare sector, focusing on stocks such as Milestone Pharmaceuticals, BioMarin Pharmaceutical, and Corbus Pharmaceuticals.
Urogen Pharma has an analyst consensus of Strong Buy, with a price target consensus of $47.50, implying a 97.9% upside from current levels. In a report issued on April 13, H.C. Wainwright also reiterated a Buy rating on the stock with a $53.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $39.98 and a one-year low of $13.12. Currently, Urogen Pharma has an average volume of 205K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
UroGen Pharma Ltd. is a clinical stage pharmaceutical company, which engages in the provision of non-surgical and localized solutions for urological pathologies to address a clinical unmet need in field of uro-oncology. Its pipeline includes upper tract urothelial carcinoma, low grade non muscle invasive bladder cancer, carcinoma in situ of the bladder, and overactive bladder. The company was founded by Asher Holzer in 2004 and is headquartered in New York, NY.